Trials / Completed
CompletedNCT00978029
Safety Study of Ragweed Allergy Immunotherapy Tablet in Subjects 50 Years of Age and Older (Study P06081)
A 28-Day Study Evaluating the Safety of Ragweed (Ambrosia Artemisiifolia) Sublingual Tablet (SCH 39641) in Adult Subjects 50 Years of Age and Older With Ragweed-Induced Rhinoconjunctivitis (Protocol No. P06081)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 203 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study was to assess the safety and tolerability of a ragweed allergy immunotherapy tablet (AIT) administered sublingually (under-the tongue) in subjects 50 years of age and older with ragweed-induced rhinoconjunctivitis, with or without asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | Placebo sublingual tablet, once daily |
| BIOLOGICAL | SCH 39641 | Allergy immunotherapy tablet (sublingual) |
| BIOLOGICAL | SCH 39641 | Allergy immunotherapy tablet (sublingual) |
Timeline
- Start date
- 2009-11-01
- Primary completion
- 2010-02-01
- Completion
- 2010-02-01
- First posted
- 2009-09-16
- Last updated
- 2017-03-03
- Results posted
- 2014-05-23
Source: ClinicalTrials.gov record NCT00978029. Inclusion in this directory is not an endorsement.